Matthew W. Foehr Purchases 13,000 Shares of Viking Therapeutics Inc (VKTX) Stock
Viking Therapeutics Inc (NASDAQ:VKTX) Director Matthew W. Foehr purchased 13,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was acquired at an average price of $1.21 per share, with a total value of $15,730.00. Following the purchase, the director now owns 39,250 shares in the company, valued at $47,492.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Viking Therapeutics Inc (NASDAQ:VKTX) traded up 0.85% during midday trading on Friday, reaching $1.18. The company’s stock had a trading volume of 3,228 shares. Viking Therapeutics Inc has a 52 week low of $0.94 and a 52 week high of $5.17. The firm’s market capitalization is $22.75 million. The company’s 50-day moving average is $1.16 and its 200 day moving average is $1.27.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.01. Analysts expect that Viking Therapeutics Inc will post ($1.00) earnings per share for the current fiscal year.
Several brokerages recently weighed in on VKTX. Maxim Group set a $5.00 price target on Viking Therapeutics and gave the company a “buy” rating in a research note on Friday, November 11th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Viking Therapeutics in a research note on Sunday, September 18th. Finally, Laidlaw cut their price target on Viking Therapeutics from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, August 11th.
A hedge fund recently raised its stake in Viking Therapeutics stock. Sio Capital Management LLC boosted its position in shares of Viking Therapeutics Inc (NASDAQ:VKTX) by 53.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 849,905 shares of the company’s stock after buying an additional 295,523 shares during the period. Viking Therapeutics accounts for about 0.8% of Sio Capital Management LLC’s portfolio, making the stock its 24th largest position. Sio Capital Management LLC owned 4.41% of Viking Therapeutics worth $1,191,000 at the end of the most recent reporting period.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Stock Ratings for Viking Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc and related stocks with our FREE daily email newsletter.